20 May 2013
Keywords: nice, wet, amd, drug, rethink, after, complaints
Article | 13 August 2007
After coming under attack over its latest draft recommendation, to provide limited access for patients with wet age-related macular
degeneration ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 August 2007
17 May 2013
© 2013 thepharmaletter.com